PMA device
Hercep Test
Agilent Technologies Singapore (International) Pte , Ltd. · System, Test, Her-2/Neu, Ihc (MVC, Class III) · First FDA decision Feb 25, 2010, newest Jun 8, 2012Breast cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Hercep"
MAUDE reports
0
Brand "Hercep", since 2015
PubMed studies
58
Mentioning "Hercep"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Hercep Test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- HERCEP TESTPMA supplement
P980018-S015 · Decided Jun 8, 2012 · 186 days after receipt · Normal 180 Day Track
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Hercep", any status and sponsor, newest update first.
No registered device study names "Hercep".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Hercep", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MVC
12 reports: 4 malfunction, 5 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0113-06 · Started Sep 29, 2005 · Posted by FDA Nov 1, 2005
Reason given: Formulation error in the Visualization Reagent (vial 3) component contained in Hercep Test kits. The error was in the concentration of Polyethylene Glycol contained in the formulation.
Cause as FDA categorized it: Other · Device type: System, Test, Her-2/Neu, Ihc (MVC)
Published research
The most relevant PubMed records for "Hercep"[tiab]. The summary above synthesizes these.
- HER2 expression in cervical cancer as a potential therapeutic target.
Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, et al. · BMC Cancer · 2004
- HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients.
Halon A, Donizy P, Biecek P, et al. · ScientificWorldJournal · 2012Research Support, Non-U.S. Gov't
- HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
Junker K, Stachetzki U, Rademacher D, et al. · Lung Cancer · 2005Clinical Trial, Clinical Trial, Phase III
- EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria.
Orekoya AA, Abdus-Salam AA, Oyesegun AR, et al. · Ecancermedicalscience · 2023
- Detection of HER-2/neu (c-erbB-2) overexpression and amplification in breast carcinomas with ambiguous immunohistochemical results. A further contribution to defining the role of fluorescent in situ hybridization.
Sidoni A, Ferri I, Cavaliere A, et al. · Anticancer Res · 2006Research Support, Non-U.S. Gov't
- [Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence].
Janane A, Hajji F, Ismail TO, et al. · Actas Urol Esp · 2011English Abstract
- Interaction between Herceptin and taxanes.
Diéras V, Beuzeboc P, Laurence V, et al. · Oncology · 2001Comparative Study, Review
- Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters?
Angiero F, Sordo RD, Dessy E, et al. · J Oral Pathol Med · 2008Comparative Study
- Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients.
Becker S, Becker-Pergola G, Fehm T, et al. · Anticancer Res · 2005
- Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test.
Matsuyama S, Kitajima Y, Sumi K, et al. · Oncol Rep · 2004
- HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.
Scheurle D, Jahanzeb M, Aronsohn RS, et al. · Anticancer Res · 2000Research Support, Non-U.S. Gov't
- Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme.
Koka V, Potti A, Forseen SE, et al. · Am J Clin Oncol · 2003Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code MVC.
- PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2026
- HerceptestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2013
- Bond Oracle HER2 Ihc SystemLeica Biosystems · PMA 2014
- PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2025
- Hercap TestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2013
- Pathway Her 2 (Clone CB11)Ventana Medical Systems, Inc. · PMA 2002
- Pathway ANTI-HCR-2/NCU (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.